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Background: Cav3.2 channels facilitate nociceptive transmission and are upregulated in DRG neurons in response
to nerve injury or peripheral inflammation. We reported that this enhancement of Cav3.2 currents in afferent
neurons is mediated by deubiquitination of the channels by the deubiquitinase USP5, and that disrupting USP5/
Cav3.2 channel interactions protected from inflammatory and neuropathic pain.
Results: Here we describe the development of a small molecule screening assay for USP5-Cav3.2 disruptors, and
report on two hits of a ~5000 compound screen - suramin and the flavonoid gossypetin. In mouse models of
inflammatory pain and neuropathic pain, both suramin and gossypetin produced dose-dependent and long-lasting
mechanical anti-hyperalgesia that was abolished or greatly attenuated in Cav3.2 null mice. Suramin and Cav3.2/
USP5 Tat-disruptor peptides were also tested in models of diabetic neuropathy and visceral pain, and provided
remarkable protection.
Conclusions: Overall, our findings provide proof of concept for a new class of analgesics that target T-type channel
deubiquitination.
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Chronic pain is a major burden on society and despite in-
creased understanding of the neurobiology of pain, only a
few novel classes of analgesic compounds have entered the
clinic. Thus the identification of new analgesics is of critical
necessity. In the primary afferent pain pathway, voltage
gated T-type calcium channels sustain neuronal firing and
appear to contribute to neurotransmitter release at afferent
terminals in the spinal dorsal horn [1,2]. This increased
neuronal excitability leads to amplification of sensory
transmission resulting in pathological pain perception [3].
Therefore, blocking T-type channels is known to mediate
analgesia. For example, systemic delivery of the poorly se-
lective T-type channel inhibitors mibefradil and ethosuxi-
mide produces antinociceptive effects in rodents [4,5].* Correspondence: zamponi@ucalgary.ca
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unless otherwise stated.More recently developed compounds with better selectivity
for T-type channels such as TTA-A2 [6], TTA-P2 [7], M12
[8] and N12 [9] are also protective in various models of in-
flammatory and neuropathic pain. The prominent T-type
channel subtype expressed in peripheral afferents is
Cav3.2, and consequently selective knockdown of the
Cav3.2 mRNA via intrathecal delivery of antisense oligonu-
cleotides produces antinociceptive and anti-hyperalgesic ef-
fects [10]. On the other hand, nerve injury or peripheral
inflammation result in upregulation of T-type calcium
channels in primary afferent fibers, which in turn contrib-
utes to pain hypersensitivity [11-14]. Our group has re-
cently identified a new cellular pathway that contributes to
this aberrant upregulation of Cav3.2 channels in chronic
pain states [15]. We showed that Cav3.2 channels associate
with USP5, a deubiquitinating enzyme [16,17] that is up-
regulated in dorsal root ganglion (DRG) and dorsal horn
tissue in response to either nerve injury or peripheral in-
flammation. This then leads to enhanced deubiquitination. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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channel density in the plasma membrane at cell bodies and
likely at nerve terminals. Knockdown of USP5 via shRNA
or preventing its association with the channel by using Tat
epitope fused disruptor peptides decreased Cav3.2 protein
levels and produced analgesia in models of inflammatory
and neuropathic pain in mice. The major benefit of this ap-
proach over conventional T-type channel inhibitors is that
it targets aberrant upregulation of the channels, while spar-
ing normal channel function.
Here, we describe the development of an ELISA-based
assay to screen a library of pharmacologically active com-
pounds (including clinically used drugs) for molecules
capable of disrupting the USP5-Cav3.2 interaction. Two of
the identified hits, suramin and gossypetin, were found to
be active in various mouse models of inflammatory and
neuropathic pain, while their activities were attenuated or
lost in Cav3.2 null mice. Hence, our findings validate small
compound inhibitors of Cav3.2 deubiquitination as a new
strategy for treating chronic pain.
Results
Blocking Cav3.2 channel deubiquitination protects from
visceral and diabetic pain
We recently reported that Tat-epitope fused peptides corre-
sponding to the USP5 interaction site on the Cav3.2 chan-
nel’s intracellular domain III-IV linker (Tat-Cav3.2-III-IV)
protected mice from CFA-induced inflammatory pain, and
from sciatic nerve ligation-induced neuropathic pain [15].
To determine if this mechanism was also active in other
pain conditions, we tested the efficacy of the peptides in
models of acute visceral pain and diabetic neuropathy. As
shown in Figure 1A and B, intraperitoneal (i.p.) adminis-
tration of acetic acid (0.9%) induced a writhing response
in mice treated with a control Tat-peptide. In con- trast,
no such writhing behavior was observed in mice
injected i.p. with vehicle (Additional file 1: Figure S1).
Mice treated via intrathecal delivery of the Tat-Cav3.2-
III-IV peptide one hour prior to the delivery of acetic
acid displayed a robust dose-dependent reduction in
the associated pain response in a blinded experiment. A
positive control (Diacerein, 50 μg/i.t., 15 minutes prior
acetic acid injection) similarly inhibited pain responses
(75 ± 3%, Additional file 1: Figure S1).
Next we tested the same peptide in in chronically
obese (ob/ob) mice as a model of diabetic neuropathy.
These mice develop diabetes and an associated poly-
neuropathy that gives rise to increased thermal and
mechanical hypersensitivity compared to non-diabetic
mice. As shown in Figure 1C, intrathecal delivery of
the Tat-Cav3.2-III-IV peptide, but not the control Tat-
3.2-CT peptide, mediated a time-dependent inhibition
of thermal hypersensitivity. Altogether, these data
show that the USP5-mediated dysregulation of Cav3.2channels occurs during both diabetic neuropathic pain
and during chemically-induced visceral pain, and dis-
rupting this process mediates analgesia.
Development of a Cav3.2-USP5 ELISA assay
While our Tat peptide approach delivered proof of con-
cept for targeting the Cav3.2-USP5 interaction as a strat-
egy for targeting various pain conditions, small organic
mimetics of these peptides are a preferred strategy for
therapeutics. We therefore developed an ELISA-based
assay for identifying small organic disruptors of the
Cav3.2-USP5 interaction. We used a 46 meric HPLC
purified synthetic peptide corresponding to the human
Cav3.2 III-IV cytosolic linker and a purified recombinant
human USP5 (long splice isoform) as the basis for the
assay. A biotinylated version of the 46 mer was conju-
gated to a neutravidin-coated plate and recombinant hu-
man USP5 was added. To detect USP5 bound to this
immobilized Cav3.2 III-IV linker peptide we used a
rabbit polyclonal anti-USP5 antibody, followed by the
addition of an HRP-conjugated secondary antibody. We
then used a QuantaBlu substrate to read the relative
fluorescent units (RFU) at excitation and emission wave-
lengths of 325 nm/440 nm. To ensure disruption of this
interaction was possible we repeated the assay in the
presence of a non-biotinylated Cav3.2 III-IV peptide (21
mer) as a competitor. USP5 robustly bound to the bio-
tinylated 46 mer Cav3.2-III-IV linker peptide, and this
interaction was reduced by > 50% in the presence of the
peptide competitor (Figure 2A) thus validating the assay.
The incomplete competition observed with the non-
biotinylated peptide is likely due to its shorter amino
acid composition (21 mer) when compared with the bio-
tinylated peptide longer version (46 mer).
Screening for modulators of the USP5-Cav3.2 interaction
The ELISA assay was refined and miniaturized to a 384
well format, and used to screen a small library of (~5000)
bioactive compounds (KD2). The resulting screen had a Z’
of 0.79 with a signal to noise of 162 (Figure 2B). A set of
18 compounds were above 50% inhibition of the Cav3.2/
USP5 interaction which was the arbitrary cut-off selected
for this screenEight compounds were confirmed with
concentration-based activity from screening plate samples,
with 6 being re-confirmed from freshly ordered powder.
These six compounds were then subjected to a secondary
screen involving co-immunoprecipitations between USP5
and Cav3.2 from whole mouse brain lysate. This led to the
confirmation of two compounds, suramin and gossypetin
whose concentration response in the ELISA assay are
shown in Figures 2C and D, respectively. Suramin is a
large molecular weight compound that contains multiple
benzene rings and is used clinically to control helminth
and protozoal infections [18]. It is commonly thought of
A B
C
Figure 1 Effects of the Tat-Cav3.2-III-IV linker peptide in mouse models of visceral pain and diabetic neuropathy. (A) Blind analyses of
writhing responses of mice treated with the Tat-3.2-III-IV linker (10.0 μg/i.t.) or the Tat-3.2-CT (control, 10.0 μg/i.t.) peptides 1 hour prior to acetic
acid injections. (B) total number of writhing responses of acetic acid injected mice treated with Tat-3.2-III-IV linker or the Tat-3.2-CT peptides. (C)
Time course of antihyperalgesic effect of the Tat-3.2-III-IV linker (10.0 μg/i.t.) or the Tat-3.2-CT (10.0 μg/i.t.) peptides delivered to diabetic neuro-
pathic (ob/ob) and wild-type mice. The experimenter was blind to the treatment in panels A, B and C. Each circle/bar represents the mean ± S.E.
M. (n=7 in panel C; and n=10 in panels A and B) and is representative of 2 independent sets of experiments. Statistical analyses were performed
by two-way ANOVA followed by a Tukey’s test (panels A and C), and unpaired Student’s t-test (panel B). The dashed line and hashtag indicate
the range of data points where diabetic neuropathic animals differed from the non-diabetic group (P<0.001).
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the other hand, is a flavonoid isolated from Hibiscus sab-
dariffa. It has antimicrobial activity, and is reported to
have health benefits in conditions such as cardiovascular
disease [20,21]. The concentration dependence of the ef-
fects of both compounds on the co-immunoprecipitation
between Cav3.2 channels and USP5 are illustrated in
Figure 3. Suramin and gossypetin inhibited USP5 binding
to Cav3.2 channels by 50-60% at 5 μM (Figure 3A-D). In
contrast, oxytetracycline hydrochloride was used as nega-
tive control as it lacked inhibitory properties in the ELISA
(Figure 3E). Altogether, these data reveal suramin and gos-
sypetin as potential small organic disruptors of USP5 inter-
actions with Cav3.2.Effect of suramin and gossypetin on mechanical
hyperalgesia produced by sciatic nerve injury
To establish if the compounds are also able to reduce mech-
anical hyperalgesia caused by peripheral nerve damage, we
tested the effects of the compounds 14 days after partial sci-
atic nerve ligation. The sciatic nerve injury produced marked
and long-lasting mechanical hyperalgesia with behavioral ab-
normalities that were evident for several weeks after the in-
jury when compared with the baseline response and sham
operated group (P< 0.001, Figure 4). When compared to the
neuropathic control group, treatment of mice with suramin
(10 μg/i.t.) or gossypetin (10 μg/i.t.), but not the vehicle (PBS,
10 μl/i.t.) produced rapid anti-hyperalgesia that remained sig-
nificant up to 90 minutes after treatment (P<0.01, Figure 4).
A B
C D
Figure 2 Cav3.2/USP5 ELISA screening results. (A) Competition affinity ELISA assay. A non-biotinylated human Cav3.21569–1589-III-IV peptide (21
mer) was used to compete off the interaction between the biotinylated Cav3.2 Cav3.21556–1602-III-IV peptide (46 mer) and hUSP5. (B) Screening of
a 5000 bioactive compound library using a 384 well capacity ELISA. A group of active compounds (~50% inhibition) were identified. (C) Structure
and concentration response curve for suramin in the ELISA assay. (D) Structure and concentration response curve for gossypetin in the
ELISA assay.
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by peripheral inflammation
To test whether suramin or gossypetin protect from inflam-
matory persistent pain in mice, we examined their effects
on mechanical hyperalgesia induced by delivery of
Complete Freund’s adjuvant (CFA) into the hindpaw. As
shown in Figure 5, CFA induces peripheral inflammation
that triggers mechanical hyperalgesia that remains signifi-
cant for days when compared with either the baseline re-
sponses or the non-inflamed group (P< 0.001). Intrathecaltreatment of mice with either suramin (1–10 μg/i.t.,
Figure 5A) or gossypetin (1–10 μg/i.t., Figure 5B), but not
with the negative control compound oxytetracycline hydro-
chloride (10 μg/i.t., Figure 5C) or vehicle (PBS, 10 μl/i.t.)
resulted in dose-dependent, rapid (15 minutes after treat-
ment) and long-lasting anti-hyperalgesia that remained
significant up to 3 hours after delivery (P < 0.001 and
P<0.01, respectively for suramin and gossypetin).
To test if the analgesic effects of suramin and gossype-
tin are mediated via modulation of Cav3.2 channels, we
Figure 3 Effect of suramin and gossypetin on USP5-Cav3.2 interactions. (A) Cav3.2 immunoprecipitates incubated with different
concentrations of suramin and probed for USP5 by Western blot. An actin loading control is shown. (B) Quantification of USP5 bound to Cav3.2
immunoprecipitates by densitometry. (C) Cav3.2 immunoprecipitates incubated with different concentrations of gossypetin and probed for USP5
by Western blot. An actin loading control is shown. (D) Quantification of USP5 bound to Cav3.2 immunoprecipitates by densitometry. (E) Cav3.2
immunoprecipitates incubated with vehicle (DMSO, lane 1), 50 μM suramin (lane 2) and 50 μM oxytetracycline (lane 3).
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mice. In response to CFA, Cav3.2 knockout mice de-
velop mechanical hypersensitivity that is similar to the
one seen in WT animals (likely due to compensatory
processes). Gossypetin (10 μg/i.t., Figure 6A, B) medi-
ated a drastically reduced, but still statistically significant
effect in Cav3.2 null mice (P<0.01), suggesting that gos-
sypetin may have more than one molecular target
in vivo. However, Cav3.2-null mice were completely in-
sensitive to treatment with suramin (10 μg/i.t., Figure 6C,
D), whereas this compound still produced a significant
effect in WT animals when they were examined in paral-
lel. Altogether, these data indicate that both compounds
mediate their actions in vivo largely (and in case of sura-
min, exclusively) via Cav3.2 channels.
To rule out the possibility that these compounds
may be direct inhibitors of Cav3.2 channels, rather
than acting by uncoupling USP5 from the channel, we
performed whole-cell patch-clamp experiments from
tsA-201 cells transfected with cDNA encoding human
Cav3.2 during which we acutely applied 10 μM sura-
min and gossypetin. No significant effects on currentamplitude or biophysical properties of the channel were
observed (7±2% inhibition (n=3) and 3±1% inhibition
(n=3) of channel activity for suramin and gossypetin, re-
spectively, which is indistinguishable from rundown), con-
sistent with an action on the USP5-Cav3.2 channel
interaction rather than direct effects on Cav3.2 channel
function.
Effects of suramin in models of acute visceral pain and
diabetic neuropathy
In light of the Tat-Cav3.2-III-IV effects described in
Figure 1, it is expected that suramin should be effective
in visceral pain and diabetic pain. Figures 7A and B
examine the effects of suramin on acetic acid induced
writhing behavior. Intrathecal (0.1 – 10 μg) or intraperi-
toneal (0.3 – 30 mg/kg) delivery of suramin one hour
prior to acetic acid injection dose-dependently inhibited
writhing behavior.
As shown in Figure 8A, a blind experiment revealed
that suramin (10 μg/i.t.) almost completely reversed
thermal hypersensitivity in chronically obese mice within
90 minutes of intrathecal delivery, in agreement with the
Figure 4 Antihyperalgesic effect of compounds in a model of neuropathic pain. Time course of the antihyperalgesic effect of intrathecally
(i.t.) delivered suramin (10.0 μg/i.t.) or gossypetin (10.0 μg/i.t.) on mechanical hyperalgesia of mice subjected to nerve injury two weeks prior to
the experiment. Each circle represents the mean ± S.E.M. (n=6-7) and is representative of 2 independent sets of experiments. Statistical analyses
were performed by two-way ANOVA followed by a Tukey’s test. The dashed line and number symbol indicate the range of data points where
injured animals differed from the sham group (P<0.001).
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mined if suramin altered endogenous USP5-Cav3.2 pro-
tein interactions in the dorsal horns from diabetic and
non-diabetic mice. Diabetic mice were treated with sura-
min (10 μg/i.t.) or vehicle and 1 hour later their dorsal
horns were isolated and Cav3.2 immunoprecipitates
were probed for USP5. Suramin inhibited USP5 binding
to Cav3.2 channels obtained from ob/ob mouse dorsal
horns while total Cav3.2 protein levels remained similar
(Figure 8B, C). We also noticed an increase in USP5
bound to the channels from diabetic mouse dorsal horns
(ob/ob + vehicle) when compared to wild type mouse
tissue (Figure 8B, D). This likely reflects an upregulation
of USP5 protein levels in neuropathic diabetic mice,
which would be consistent with our previous findings in
CCI and CFA animal pain models [15]. Altogether, these
data fit with our observations with the Tat-Cav3.2-III-IV
peptide and highlight suramin as a broadly acting anal-
gesic in a wide range of pain conditions.
Discussion
We recently reported that USP5-mediated deubiquitina-
tion of Cav3.2 channels in mouse dorsal root ganglia
and dorsal horns is enhanced following peripheral in-
flammation or nerve injury, leading to increased T-type
calcium currents that in turn give rise to pain hypersen-
sitivity [15]. We showed that depletion of USP5, or its
uncoupling from Cav3.2 channels via delivery of Tat
peptides prevented and/or reversed the pain phenotypein models of peripheral inflammation (i.e., formalin and
CFA) and peripheral nerve injury (i.e., partial sciatic
nerve ligation). Here, we have extended our observation
to two additional pain models – diabetic neuropathic
pain and acute visceral pain. Diabetic neuropathy is one
of the most prevalent complications associated with dia-
betes, with approximately half of type 1 and 2 diabetic
patients being affected [22-24]. Diabetic neuropathy can
lead to the development of chronic neuropathic pain, a
debilitating condition that affects ~ 20% of diabetics and
is poorly managed with current treatment regimens
[25-28]. Along these lines, visceral pain is a major symp-
tom of conditions such as inflammatory bowel disease
and is challenging to manage [29]. Our observations
with the Tat-Cav3.2-III-IV peptide thus suggest that tar-
geting Cav3.2 deubiquitination by USP5 is a potential
new target for therapeutic approaches to pain hypersen-
sitivity in diabetes and pain conditions associated with
inflammatory disorders of the gut.
The observation that small organic molecules can mimic
the effect of the Tat peptide in vitro and in vivo is particu-
larly exciting and it is remarkable to have identified mul-
tiple “hits” in a relatively small screen. The biflavenoid
gossypetin (318 Da) and the polysulphonated naphtylurea
suramin (~1.3 kDa) are vastly different in size, and yet both
compounds effectively disrupted USP5 binding to the
Cav3.2 III-IV linker region. Suramin is a structurally sym-
metric compound with two arms that each contain a
sulfonated naphthalene structure. The latter is reminiscent
Figure 5 Antihyperalgesic effect of compounds against persistent inflammatory pain. Time course and dose-dependent antihyperalgesic
effect of (A) suramin (1.0-10.0 μg/i.t.), (B) gossypetin (1.0-10.0 μg/i.t.) and (C) oxytetracycline (10.0 μg/i.t.) on mechanical hyperalgesia of mice
injected with CFA. Each circle represents the mean ± S.E.M. (n=6-7) and is representative of 2 independent sets of experiments. Statistical analyses
were performed by two-way ANOVA followed by a Tukey’s test. The dashed line and number symbol indicate the range of data points where
injured animals differed from the group injected intraplantarly with PBS (P<0.001).
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gesting the possibility that the disruption of USP5-Cav3.2 in-
teractions may involve this bicyclic aromatic structure. It will
thus be interesting to conduct additional structure-activity
relationship studies around the bicyclic aromatic core struc-
ture. By contrast, oxytetracycline is based on an octahydrote-
tracene scaffold which contains four fused benzene rings,
and was inactive in both biochemical and in vivo assays.
To our knowledge, there is not a single report in the
scientific literature that directly links the flavonoid gos-
sypetin to pain relief, however, antinociceptive effects of
crude hibiscus extract in an acetic acid writhing test in
mice [30] have been reported, and there is anecdotal evi-
dence that hibiscus tea may aid the relief of menstrual
pain. In contrast, suramin has been reported to have
antinociceptive effects in a formalin model of inflamma-
tory pain [31-33] and a recent study has reported that
suramin reduces mechanical hypersensitivity associatedwith trigeminal neuropathic pain [34]. Our data showing
protection from sciatic nerve injury induced neuropathic
pain fits with the latter observation. In addition, our data
show that suramin protects from diabetic neuropathy,
visceral pain and pain associated with persistent inflam-
mation of the hindpaw (i.e., CFA model).
It is noteworthy that prior studies reporting analgesic ef-
fects of suramin have attributed its effects to antagonism
of P2X receptors. Indeed suramin blocks P2X2/3 hetero-
meric receptors with an affinity in the lower micromolar
range [35]. In cultured rat DRG neurons, sub micromolar
concentrations of suramin have been shown to block na-
tive P2X receptors activated by 10 μM ATP [36]. This
could lead one to conclude that the observed analgesic ef-
fects in our study are mediated by P2X receptor antagon-
ism. However, our data show that the effects of suramin
were completely lost in Cav3.2 null mice. This in turn indi-
cates that suramin acts, at least in the CFA model, via
A B
C D
Figure 6 Effect of compounds on hyperalgesia of Cav3.2 null mice. (A) Blind-analyses of the time course of mechanical hyperalgesia of CFA injected
Cav3.2 null and WT mice treated with gossypetin (10.0 μg/i.t.). (B) Data for mechanical hyperalgesia of Cav3.2 null and WT mice when measured
15 minutes after treatment with gossypetin. (C) Mechanical hyperalgesia of CFA injected Cav3.2 null and WT mice treated with suramin (10.0 μg/i.t.). (D)
Data for mechanical hyperalgesia of Cav3.2 null and WT mice when measured 15 minutes after treatment with suramin. Each circle/bar represents the
mean ± S.E.M. (n=6-7) and data are representative of 2 independent sets of experiments. Statistical analyses were performed by two-way ANOVA
followed by Tukey’s test. The dashed line and hashtag indicate the range of data points where injured animals differed from the sham treated group
(P<0.001). Ns: non-significant.
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P2X receptor. Furthermore, the activity profile of suramin
mirrored that observed with the Tat-Cav3.2-III-IV peptide
here and in our previous work [15], and with that of gossy-
petin, consistent with a common molecular mechanism of
action. Only when we tested suramin in Cav3.2 null mice
at 5 fold higher doses (50 μg/i.t.), we observed an add-
itional antihyperalgesic effect with inhibition of 43 ± 16%
(n=6, P<0.05), perhaps due to the antagonism of P2X re-
ceptors at higher suramin concentrations.
While suramin was initially designed to treat parasitic in-
fections, this compound also has been tested as a potentialtreatment for various cancers [37]. Interestingly, in three
clinical trials that examined the efficacy of suramin in the
treatment of prostate cancers, patients reported reduced
pain, and there was reduced opioid intake [38-40]. While
these analgesic effects were not systematically investigated
in a randomized clinical trial, these observations are con-
sistent with our findings in mice and suggest potential ap-
plications for suramin as a pain therapeutic. Since both
suramin and gossypetin are already approved for use in
humans, these compounds could be readily entered into
clinical trials for pain. Dietary supplements containing gos-
sypetin are available and have been tested in clinical trials
Figure 7 Effects of suramin on acute visceral pain. (A) Analyses of writhing responses of intrathecally treated mice with suramin (0.1-10.0 μg/i.
t.)1 hour prior to acetic acid injections. (B). Effect on intraperitoneally delivered suramin (0.3-30 mg/kg, 1 hour prior ) on writhing responses
induced by acetic acid. Each circle represents the mean ± S.E.M. (n=8-10) and is representative of 2 independent sets of experiments. Statistical
analyses were performed by two-way ANOVA followed by a Tukey’s test. The dashed line and number symbol indicate the range of data points
where diabetic neuropathic animals differed from the non-diabetic group (P<0.001).
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man studies evaluating the potential beneficial effects of
gossypetin in treating pain could be initiated quickly.
Conclusions
Overall, our results indicate that disrupting the interaction
between the deubiquitinase USP5 and Cav3.2 calcium
channels via a small organic molecule is a promising new
strategy for treating a spectrum of chronic pain states. The
identification of both suramin and gossypetin as examples
of such compounds, and their abilities to reverse pain
hypersensitivity may potentially open an avenue for rapidly
translating our findings towards clinical use.
Methods
Compounds and reagents
The following compounds were used in the study: Complete
Freund’s Adjuvant (CFA) (Sigma Chemical Company, St.
Louis, MO, USA). Suramin sodium salt (Cat# 574625, EMD
Millipore) Gossypetin (Cat# G-500, Indofine Chemical
Company) and oxytetracycline hydrochloride (Cat# O5875,
Sigma). When compounds were delivered by the intraperi-
toneal (i.p.) route, a constant volume of 10 ml/kg body
weight was injected. When compounds were administered
intrathecally (i.t.), 10 μl were injected. Appropriate vehicle
(PBS)-treated groups were assessed simultaneously. Com-
pounds delivered to animals were dissolved in PBS.
ELISA peptide competition assays
Recombinant human USP5 or isopeptidase T long isoform
(0.5 μg) (Enzo Life Sciences) was incubated or not with50 μg of non-biotinylated peptide (human Cav3.21569–1589-
III-IV) for 1 hour tumbling at room temperature (RT).
Neutravidin coated plates (Piercenet) were washed with
100 μl buffer (50 mM Tris, 150 mM NaCl+0.05% Tween-
20) prior to addition of peptides. Then 5 μg of the Cav3.2
biotinylated peptide III-IV linker (human Cav3.21556–1602-
III-IV) was added to the 96-well plate with the preincu-
bated complex of recombinant hUSP5 long (0.5 μg/
1.25 μl) + non-biotinylated peptide for 1 hr incubation at
RT. Wells were washed three times with 100 μl Tris-NaCl-
150, shaking at RT for 10 minutes each, and 100 μl block-
ing buffer-TBS (Piercenet) was added to wells. Plates were
immediately emptied. 100 μl of blocking buffer was added
and samples were incubated for 1 hr at RT while shaking.
Plates were inverted to clear the wells. Plates were then
dried three times on a stack of paper towels. 100 μl rabbit
primary anti-USP5 antibody (1:1,000 dilution; Protein-
Tech Group, Inc.) was added to each well and incubated
for 1 hr at RT. Plates were inverted to empty wells and
washed three times with 200 μl of wash buffer (50 mM
Tris, 150 mM NaCl + 0.05%Tween-20) for 10 minutes
each on a shaking platform. Plates were dried three times
as before. Samples were incubated with anti-rabbit
HRPconjugated secondary antibody (Jackson Immunore-
search Labs; 1:10,000 dilution) for 45 min at RT. Plates
were inverted and dried as before. 100 μl of QuantaBluWS
(Pierce) (9 parts substrate solution + 1 part stable peroxide)
was added to each well and incubated for 1.5-90 min at
RT. Peroxidase activity was stopped by adding 100 μl of
QuantaBlu Stop Solution (Pierce). The excitation and
emission maxima for QuantaBlu Fluorogenic Peroxidase
Figure 8 Effects of suramin on diabetic neuropathy. Blind analyses of time course of antihyperalgesic effect of suramin (10.0 μg/i.t.) delivered
to diabetic neuropathic (ob/ob) and wild-type mice. The experimenter was blind to the treatment in panel A. Each circle/bar represents the mean
± S.E.M. (n=6) and is representative of 2 independent sets of experiments. Statistical analyses were performed by two-way ANOVA followed by a
Tukey’s test. The dashed line and number symbol indicate the range of data points where diabetic neuropathic animals differed from the
non-diabetic group (P<0.001). (B) Cav3.2 immunoprecipitates from dorsal horns from naïve mice (lane 1), or from diabetic mice treated with
either vehicle (lane 2) or suramin (lane 3), were probed for USP5 and analyzed by western blot 90 minutes after i.t. treatment. A blot for actin is shown
as control (bottom panel). (C) Cav3.2 immunoprecipitates from dorsal horns from naïve mice (lane 1), or from diabetic mice treated with either vehicle
(lane 2) or suramin (lane 3), were probed for Cav3.2 channels, as control. (D) Quantification of USP5 bound to Cav3.2 immunoprecipitates by
densitometry. Statistical analysis for mice treated with vehicle vs. mice treated with suramin was done via a Student’s t-test (*P <0.05).
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ioSkan microplate reader (Thermo Scientific) was used to
take relative fluorescence unit (RFU) readings (Ex/Em:
325/440 nm).
Cav3.2/USP5 ELISA screening assay
Black high-binding 384-well plates (Corning) were incu-
bated (overnight, 4°C) with 4 μg/ml Neutravidin (Thermo
Scientific) in 40 μl PBS with 0.05% azide which was added
using a WellMate dispenser (Matrix Technologies). The
plates were washed 3 times with 90 μl Tris buffer (50 mM
Tris, 150 mM NaCL, pH 7.5) with a plate washer (BioTek),
after which plates were incubated with 80 μl blocking buf-
fer (Tris buffer plus 1% BSA (Sigma);1 hr, RT). Plates were
then washed 3 times with Tris buffer and the WellMate
used to add 25 μl Tris buffer per well. A 5,000 compoundlibrary from CDRD containing known drugs and bioac-
tives, known as the KD2 library, was pinned using a Plate-
Mate Plus machine (Matrix Technologies) and a FP3
pintool, to give a final compound concentration of 6.3 μM
per well. The biotinylated Cav3.2 III-IV linker peptide
(0.0039 μg/μl Genemed synthesis Inc.) was added in 15 μl
Tris buffer (1 hr, RT). This was followed by 15 μl of
0.00078 μg/μl USP5 protein (Enzo Life Sciences) in Tris
buffer added to all wells apart from the negative control
wells (1 hr, RT). Wells were washed three times with wash
buffer (Tris buffer plus 0.05% Tween (Fisher)), followed by
the addition of anti-USP5 primary antibody (Proteintech
Group) in 30 μl blocking buffer (1:5000 dilution, 1 hr, RT)
per well. Wells were subsequently washed 3 times with
wash buffer, after which anti-rabbit HRP-conjugated sec-
ondary antibody (Jackson Immunoresearch Labs) was
Gadotti et al. Molecular Pain  (2015) 11:12 Page 11 of 13added in 30 μl blocking buffer, (1:15,000 dilution, 1 hr, RT)
per well. After washing three times, 30 μl QuantaBlu sub-
strate (Pierce) was added per well (5 min, RT) followed by
30 μl QuantaBlu stop solution. A VarioSkan microplate
reader (Thermo Scientific) was used to take RFU readings
(Ex/Em: 325/440 nm). The raw data obtained were con-
verted to % inhibition and Z’ and signal to noise (S/N)
values were calculated.
Co-immunoprecipitation assays
Mouse brain tissue was lysed in a modified RIPA buffer (in
mM; 50 Tris, 100 NaCl, 0.2% (v/v) Triton X-100, 0.2% (v/v)
NP-40, 10 EDTA + protease inhibitor cocktail, pH 7.5) that
was used to co-immunoprecipitate Cav3.2 channels with
USP5 protein. Lysates from mouse dorsal horn tissue were
prepared by sonicating samples at 60% pulse for 10 seconds
and by centrifugation at 13,000 rpm for 15 minutes at 4°C.
Supernatants were transferred to new tubes and solubilized
proteins were incubated with 50 μl of Protein G/A beads
(Piercenet) and 2 μg of anti-Cav3.2 (H-300, Santa Cruz
Biotechnologies, Inc.,) antibody overnight while tumbling at
4°C. Total inputs were taken from whole cell samples
representing 4% of total protein and probed for actin. Co-
immunoprecipitates were washed twice with (mM) 150
NaCl 50 Tris pH 7.5 buffer, beads were aspirated to dry-
ness. Laemmli buffer was added and samples were incu-
bated at 96°C for 7 minutes. Eluted samples were loaded on
a 10% Tris-glycine gel and resolved using SDS-PAGE.
Samples were transferred to 0.45 mm polyvinylide-
nedifluoride (PDVF) membranes (Millipore) and western
blot analysis was performed using anti-actin (Sigma), and
anti-USP5 (ProteinTech Group, Inc.) antibodies. Western
blot quantification was performed using densitometry
analysis (Quantity One-BioRad software). Student’s t-tests
for unpaired data were performed to determine statistical
significance.
Animals
Experiments were performed after approval of an animal
protocol by the Institutional Animal Care and Use Com-
mittee and all efforts were made to minimize animal suffer-
ing according to the policies and recommendations of the
International Association for the Study of Pain. In this
study we used male C57BL/6 J (wild-type), Cacna1h
(Cav3.2 null, background C57BL/6 J) mice (mus musculus,
22-28 g, 8 weeks old) or morbidly obese (ob/ob, back-
ground C57BL/6 J, 14–17 weeks old) purchased from the
Jackson Laboratory. Animals were housed at a maximum
of five per cage (30 × 20 × 15 cm) and with water and food
ad libitum. They were kept in controlled temperature of
23 ± 1°C on a 12 h light/dark cycles (lights on at 7:00 a.m.)
and all experiments were performed between 10 am and
3 pm. Different cohorts of mice were used for each test.
The observer was blind to the experimental conditions inthe experiment examining the effect of the Tat-III-IV-linker
peptide and suramin when delivered intrathecal to mice on
acetic acid model. Diabetic (ob/ob) mice and their age-
matched wild-type counterparts (C57BL/6) were studied
for thermal hyperalgesia between the ages of 14 and
17 weeks. Upon their arrival at the age of 6 weeks, mouse
body weights and blood glucose levels were monitored
monthly by analyzing tail blood samples by using a One
Touch-Verio glucometer (Johnson & Johnson, New
Brunswick-NJ). Neither suramin nor the Tat-III-IV-linker
peptide altered glucose levels of diabetic animals. Obese
mice were tested for thermal hyperalgesia due to their ex-
cessive bodyweight that compromises mechanical thresh-
old measurements using the digital aesthesiometer. The
experimenter was blind to the experimental conditions in
the experiment evaluating the antinocicpetive action of the
Tat-disruptor peptide on acetic acid test (Figure 1A, B); the
antihyperlagesic action of the Tat-disruptor peptide on dia-
betic neuropathy (Figure 8A), and the effect of suramin
and gossypetin on chronic inflammatory pain (CFA model)
in either wild-type or Cav3.2 null mice (Figure 6).
Persistent inflammatory pain induced by CFA
To induce mechanical hyperalgesia produced by peripheral
inflammation, 20 μl of Complete Freund’s Adjuvant (CFA)
was injected subcutaneously in the plantar surface of the
right hindpaw (i.pl.) [42]. Sham groups received 20 μl of
PBS in the ipsilateral paw. Animals were treated with either
suramin (1–10 μg/i.t.), gossypetin (1–10 μg/i.t.), vehicle
(10 μl/i.t.) or oxytetracycline hydrochloride (10 μg/i.t., also
used as negative control), 3 days following CFA injection
and their mechanical withdrawal threshold were subse-
quently tested.
Mononeuropathy caused by partial sciatic nerve injury
In order to produce neuropathic pain in mice, a partial
ligation of the sciatic nerve was performed according to
[43]. Briefly, under isoflurane anesthesia and aseptic condi-
tions the right sciatic nerve was exposed at high-thigh level
and a 6–0 silk suture was inserted into the nerve and
tightly ligated so that the dorsal 1/3-1/2 of the nerve thick-
ness was trapped in the ligature and the wound was closed
with 4–0 silk suture. In all mice the left (contralateral) leg
and sciatic nerve were untouched. In sham operated mice
the nerve was left intact. Fourteen days later the operated
mice received suramin (10 μg/i.t.), gossypetin (10 μg/i.t.),
or vehicle (10 μl/i.t. of PBS). Measurements of mechanical
withdrawal thresholds were taken as described below.
Acute visceral pain
To produce acute visceral pain, mice were injected
with 0.45 mL of a 0.9% v/v solution of acetic acid in
PBS intraperitoneally. This results in a release of pro-
nociceptive inflammatory mediators from resident
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characterized by writhing, full extension and contrac-
tion of the abdomen [45,46]. One hour prior to acetic
acid injection, mice were treated intrathecally with the
Tat-3.2-III-IV-linker (10 μg/i.t.), the Tat-3.2-CT (con-
trol, 10 μg/i.t.) peptides, with suramin either intra-
thecally (0.1-10 μg/i.t.) or intraperitoneally (0.3-30 mg/
kg, i.p.). After acetic acid administration, animals were
immediately placed in individual observation chambers
and numbers of writhes were counted in 5-minute in-
tervals for 30 minutes after acetic acid injection.
Mechanical hyperalgesia
For evaluation of mechanical hyperalgesia we used the
digital plantar aesthesiometer (DPA, UgoBasile, Varese,
Italy) according to our previous publication [15]. Mice were
placed individually in a small enclosed testing arena (20 cm
× 18.5 cm × 13 cm, length × width × height) on top of a
grid floor while they acclimated in the experimental room
for a period of at least 90 minutes before the measure-
ments. The aesthesiometer was positioned underneath the
animal with the filament directly under the plantar surface
of the ipsilateral hind paw. To verify the time-dependence
effect of suramin and gossypetin, mechanical withdrawal
thresholds were determined at 1 day prior to CFA injection
(Baseline), and 3 days after CFA injection at 0, 15, 45, 90
and 180 minutes after treatment of mice with either sura-
min, gossypetin or oxytetracycline. Each paw was tested
three times per session.
Thermal hyperalgesia
Thermal hyperalgesia was examined on diabetic and non-
diabetic (ob/ob) mice by measuring the latency to with-
drawal of right hind paws on a focused beam of radiant
heat (IR=30) of a Plantar Test apparatus (UgoBasile,
Varese, Italy). Animals were placed individually in a small
enclosed testing arena (20 cm × 18.5 cm × 13 cm, length ×
width × height) on top of a wire mesh floor. Mice were
allowed to acclimate for a period of at least 90 minutes.
The device was positioned beneath the animal, so that the
radiant heat was directly under the plantar surface of the
ipsilateral hind paw. Three trials for each mouse were per-
formed. The apparatus was set at a cut-off time of 30 s to
avoid tissue damage. Thermal hyperalgesia was evaluated
immediately prior to the treatments (Time 0) and 15, 45,
90 and 180 minutes after treatment when mice were be-
tween 14–17 weeks old.
Intrathecal drug treatment
Intrathecal injections were perform in fully conscious
mice as previously described [47]. Briefly, mice were
manually restrained, the dorsal fur of each mouse was
shaved, the spinal column was arched, and a 30-gauge
needle attached in a PE20 Polyethylene tube to a 25-μlHamilton microsyringe (Hamilton, Birmingham, UK) was
inserted into the subdural space between the L4 and L5 ver-
tebrae. Accurate positioning of the needle tip was con-
firmed by a characteristic tail-flick response of animal
when the needle if correctly positioned. Intrathecal injec-
tions of 10 μl were delivered over a period of 5 seconds.
Statistical analysis
For biochemical results data are presented as mean ± S.E.
M. and statistical significance was determined using Stu-
dent’s t-test unless stated otherwise: *P <0.05; **P <0.01;
***P <0.001; NS = statistically not different. For behavioral
experiments, data are presented as means ± SEM and eval-
uated by one-way, two-way or three-way analysis of vari-
ance (ANOVA) followed by a Tukey’s test. A value of
P < 0.05 was considered to be significant. (*P <0.05; **P <0.01;
***P <0.001; NS = not different).
Additional file
Additional file 1: Figure S1. Control experiments for acetic acid test.
Writhing behavior in response to intraperitoneal injection of PBS, or
acetic acid in the presence of either vehicle or the anti-inflammatory
Diacerein. Note that PBS injection does not result in writhing behavior,
whereas acetic acid produces writhes that can be blocked by Diacerein.
Each bar includes data from five mice.
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